Skip to content

US · PULM · BIOTECHNOLOGY

Pulmatrix, Inc. (PULM) intrinsic value and stock valuation

$1.27as of 2026-11-21 · Mkt cap 6.06M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Pulmatrix, Inc. DCF and intrinsic value

InvestorsCraft values PULM with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PULM’s statements →

Pulmatrix, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Framingham, MA 01701 pulmatrix.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$0.00
20122025
Net income
-$-5.16M
20122025
Free cash flow
-$-5.43M
20122025
Total equity
$3.81M-30.3% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$0.00$7.81M$7.3M$6.07M$5.17M
Operating income-$-5.17M-$-9.76M-$-14.74M-$-18.95M-$-20.17M
Net income-$-5.16M-$-9.56M-$-14.12M-$-18.84M-$-20.17M
EPSd-$-1.41M-$-2.62M-$-3.87M-$-5.46M-$-7.44M
Operating cash flow-$-5.43M-$-10.72M-$-15.98M-$-19.36M-$-19.73M
Capital expenditure$0.00-$-400K-$-680K-$-90K-$-140K
Free cash flow-$-5.43M-$-11.11M-$-16.66M-$-19.44M-$-19.87M
Total assets$4.14M$9.94M$34M$41M$58.8M
Total debt$0.00$0.00$8.76M$860K$2.29M
Net debt-$-4.09M-$-9.52M-$-10.42M-$-34.77M-$-51.55M
Total equity$3.81M$8.95M$18M$31.1M$47.5M
Cash and short-term investments$4.09M$9.52M$19.2M$35.6M$53.8M
Income statement
20252024202320222021
Revenue$0.00$7.81M$7.3M$6.07M$5.17M
Cost of revenue$40K$7.17M$15.5M$18.2M$15.4M
Gross profit-$-40K$640K-$-8.22M-$-12.17M-$-10.21M
Research and development expenses$40K$7.17M$15.5M$18.2M$15.4M
Selling, general and administrative expenses$5.13M$7.79M$6.52M$6.78M$6.38M
Other expenses-$-40K-$-4.55M-$-15.52M-$-18.24M-$-11.8M
Operating expenses$5.13M$10.4M$6.52M$6.78M$9.95M
Cost and expenses$5.17M$17.6M$22M$25M$25.3M
Interest income$140K$470K$870K$310K$10K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$0.00$110K$130K$160K$170K
Ebitda-$-5.16M-$-7.04M-$-13.99M-$-18.67M-$-16.42M
Operating income-$-5.17M-$-9.76M-$-14.74M-$-18.95M-$-20.17M
Total other income/expenses, net$10K$200K$620K$110K-$0.00
Income before tax-$-5.16M-$-9.56M-$-14.12M-$-18.84M-$-20.17M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-5.16M-$-9.56M-$-14.12M-$-18.84M-$-20.17M
Weighted average shares outstanding$3.65M$3.65M$3.65M$3.45M$2.34M
Weighted average diluted shares outstanding$3.65M$3.65M$3.65M$3.45M$2.71M
Balance sheet
20252024202320222021
Cash and short-term investments$4.09M$9.52M$19.2M$35.6M$53.8M
Net receivables$0.00$0.00$930K$1.3M$70K
Inventory$0.00$0.00$0.00$150K$0.00
Total current assets$4.13M$9.92M$20.8M$38.2M$54.8M
Property, plant and equipment, net$0.00$0.00$11.5M$940K$2.41M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$10K$10K$1.47M$1.47M$1.62M
Total non-current assets$10K$20K$13.1M$2.81M$4.04M
Total assets$4.14M$9.94M$34M$41M$58.8M
Accounts payable$270K$810K$1.92M$1.19M$840K
Short-term debt$0.00$0.00$430K$860K$1.43M
Deferred revenue$0.00$0.00$620K$1.34M$940K
Total current liabilities$330K$930K$3.91M$5.02M$4.44M
Long-term debt$0.00$0.00$8.33M$0.00$860K
Deferred revenue, non-current$0.00$0.00$3.73M$4.82M$6.07M
Total non-current liabilities$0.00$70K$12.1M$4.82M$6.93M
Capital lease obligations$0.00$0.00$8.76M$860K$2.29M
Total liabilities$330K$1M$16M$9.84M$11.4M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-302.32M-$-297.16M-$-287.6M-$-273.48M-$-254.64M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$3.81M$8.95M$18M$31.1M$47.5M
Total investments$10K$10K$1.47M$1.47M$1.62M
Total debt$0.00$0.00$8.76M$860K$2.29M
Net debt-$-4.09M-$-9.52M-$-10.42M-$-34.77M-$-51.55M
Cash flow statement
20252024202320222021
Net income-$-5.16M-$-9.56M-$-14.12M-$-18.84M-$-20.17M
Depreciation and amortization$0.00$430K$1.48M$1.54M$1.24M
Stock-based compensation$30K$510K$950K$1.11M$1.16M
Change in working capital-$-230K-$-4.79M-$-4.3M-$-3.18M-$-5.53M
Accounts receivable$0.00$930K$370K-$-1.23M$20K
Inventory$0.00$0.00$0.00$0.00-$-2.07M
Accounts payable-$-540K-$-1.11M$730K$510K-$-150K
Net cash provided by operating activities-$-5.43M-$-10.72M-$-15.98M-$-19.36M-$-19.73M
Investments in property, plant and equipment$0.00-$-400K-$-680K-$-90K-$-140K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00-$-400K-$-680K-$-90K-$-140K
Common stock issued$0.00$0.00$50K$1.38M$37.1M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00-$-3.2M
Net cash used for financing activities$0.00$0.00$50K$1.23M$43.5M
Net change in cash-$-5.43M-$-11.11M-$-16.61M-$-18.21M$23.6M
Cash at end of period$4.1M$9.53M$20.6M$37.3M$55.5M
Operating cash flow-$-5.43M-$-10.72M-$-15.98M-$-19.36M-$-19.73M
Capital expenditure$0.00-$-400K-$-680K-$-90K-$-140K
Free cash flow-$-5.43M-$-11.11M-$-16.66M-$-19.44M-$-19.87M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Pulmatrix, Inc.

        Pulmatrix, Inc. (PULM) is a clinical-stage biotechnology firm focused on creating and advancing inhaled treatments. The company's primary goal is to address significant unmet medical needs in respiratory and other diseases within the United States. Central to their approach is the innovative iSPERSE (inhaled small particles easily respirable and emitted) technology. This proprietary platform allows for the precise delivery of both small and large molecule therapeutics directly into the lungs, achieving either localized effects or systemic distribution throughout the body. Pulmatrix's development pipeline includes several key candidates: Pulmazole: An inhaled antifungal drug being developed to treat allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis. PUR1800: A narrow spectrum kinase inhibitor currently undergoing Phase 1b clinical trials for individuals suffering from stable moderate-to-severe chronic obstructive pulmonary disease (COPD). PUR3100: An iSPERSE-formulated version of dihydroergotamine, intended for the rapid relief of acute migraine attacks. The company also maintains strategic collaborations, including a licensing arrangement with RespiVert Ltd. for access to a range of kinase inhibitor drug candidates, a partnership with Cipla Technologies LLC for the development and commercialization of Pulmazole, and a collaboration and license agreement with Sensory Cloud, Inc. Established in 2003, Pulmatrix, Inc. is headquartered in Lexington, Massachusetts.

        CEO
        Peter Ludlum
        Employees
        2
        Beta
        1.90

        Explore

        Frequently asked questions

        What is the intrinsic value of Pulmatrix, Inc. (PULM)?

        InvestorsCraft does not currently publish an intrinsic value for PULM. How the IC value is calculated.

        Is PULM undervalued?

        InvestorsCraft does not publish an undervaluation signal for PULM at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.